Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NLS Pharmaceutics Ltd. - Common Shares (NQ: NLSP )

1.910 -0.130 (-6.37%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 120,672
Open 1.960
Bid (Size) 1.900 (5)
Ask (Size) 2.050 (1)
Prev. Close 2.040
Today's Range 1.891 - 2.050
52wk Range 1.730 - 20.80
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's Going On With NLS Pharmaceuticals Stock Monday?
NLS Pharmaceuticals stock is moving higher on Monday after the company announced it filed a F-4 registration statement with the SEC ahead of a proposed merger. 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment
Via ACCESSWIRE

Performance

YTD
-12.39%
-12.39%
1 Month
-3.54%
-3.54%
3 Month
-59.87%
-59.87%
6 Month
-73.50%
-73.50%
1 Year
-90.03%
-90.03%

More News

Read More
NLS Pharmaceutics CEO Issues Letter to Shareholders
Via ACCESSWIRE
NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders
Via ACCESSWIRE
NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders
Via ACCESSWIRE
What's Going On With NLS Pharmaceutics Shares Monday?
Via Benzinga
NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge
Via ACCESSWIRE
Why Yum China Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements
Via ACCESSWIRE
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules
Via ACCESSWIRE
Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket
Via Benzinga
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split
Via ACCESSWIRE
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Dow Edges Lower; Ventyx Biosciences Shares Plummet
Via Benzinga
Topics Stocks
Exposures US Equities
Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump
Via Benzinga
Exposures Fossil Fuels
Tivic Health Systems (TIVC) Stock Pops Another 39%
Via InvestorPlace
Why Is NLS Pharmaceutics (NLSP) Stock Up 48% Today?
Via InvestorPlace
NLS Pharmaceutics Announces Registered Direct Offering
Via ACCESSWIRE
NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments
Via ACCESSWIRE
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements
Via ACCESSWIRE
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
PLTR Stock: Palantir Bags New Partnership With ARPA-H for AI/ML
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Dow Edges Lower; US Current Account Deficit Widens In Q1
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today?
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.